28 Apr 2017 12:15
For immediate release | 28 April 2017 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Annual Report and AGM Notice
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, confirms that it has today published the following documents on its website, investors.alliancepharmaceuticals.com/, in compliance with AIM rule 26:
· the Annual Report for the year ended 31 December 2016
· an explanatory circular containing the notice of the Annual General Meeting, to be held on 25 May 2017
· a proxy form for shareholders to vote at the AGM
Hard copies of all three documents have been posted to all shareholders.
This announcement is released in compliance with AIM rule 20.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer | |
Rob Bellhouse, Company Secretary | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)